GCDH
Basic information
Region (hg38): 19:12891128-12915126
Links
Phenotypes
GenCC
Source:
- glutaryl-CoA dehydrogenase deficiency (Definitive), mode of inheritance: AR
- glutaryl-CoA dehydrogenase deficiency (Definitive), mode of inheritance: AR
- glutaryl-CoA dehydrogenase deficiency (Moderate), mode of inheritance: AR
- glutaryl-CoA dehydrogenase deficiency (Strong), mode of inheritance: AR
- glutaryl-CoA dehydrogenase deficiency (Supportive), mode of inheritance: AR
- glutaryl-CoA dehydrogenase deficiency (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Glutaric aciduria, type I | AR | Biochemical | Early detection to allow treatment to decrease morbidity/mortality related to acute metabolic compensation, as well as dietary measures to reduce lysine oxidation and influx (eg, with low lysine diet and arginine supplementation) and increase glutaryl-CoA detoxification (eg, with carnitine supplementation) can be beneficial | Biochemical; Cardiovascular; Neurologic | 1137568; 624191; 3658174; 2027453; 1951469; 8139602; 8541831; 7564239; 8552212; 8900227; 11060535; 10699052; 12473778; 12888985; 15505396; 15954035; 15985591; 16641220; 17188916; 17203377; 17478444; 17622945; 17957492; 18775269; 19260933; 20084589; 20301313; 20732827; 21031586; 21912879; 22520952; 23225040; 23395213; 23884036 |
ClinVar
This is a list of variants' phenotypes submitted to
- Glutaric aciduria, type 1 (110 variants)
- not provided (16 variants)
- GCDH-related disorder (2 variants)
- Congenital dyserythropoietic anemia type 4;Fetal hemoglobin quantitative trait locus 6;BLOOD GROUP--LUTHERAN INHIBITOR (1 variants)
- Hypomyelinating leukodystrophy 2 (1 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GCDH gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 217 | 222 | ||||
missense | 68 | 87 | 100 | 257 | ||
nonsense | 14 | 24 | 38 | |||
start loss | 3 | |||||
frameshift | 18 | 26 | 44 | |||
inframe indel | 7 | |||||
splice donor/acceptor (+/-2bp) | 19 | 28 | ||||
splice region | 1 | 1 | 3 | 38 | 43 | |
non coding | 17 | 104 | 20 | 141 | ||
Total | 110 | 160 | 125 | 323 | 22 |
Highest pathogenic variant AF is 0.000263
Variants in GCDH
This is a list of pathogenic ClinVar variants found in the GCDH region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
19-12891168-T-C | Glutaric aciduria, type 1 | Uncertain significance (Jan 13, 2018) | ||
19-12891169-G-GT | Elevated circulating glutaric acid concentration | Uncertain significance (Jun 14, 2016) | ||
19-12891187-C-T | Glutaric aciduria, type 1 | Uncertain significance (Jan 13, 2018) | ||
19-12891188-G-A | Glutaric aciduria, type 1 | Uncertain significance (Jan 13, 2018) | ||
19-12891190-G-A | Glutaric aciduria, type 1 | Uncertain significance (Jan 22, 2019) | ||
19-12891202-G-A | not specified • Glutaric aciduria, type 1 | Conflicting classifications of pathogenicity (Jan 13, 2018) | ||
19-12891205-A-G | not specified | Likely benign (Aug 11, 2016) | ||
19-12891211-G-A | Glutaric aciduria, type 1 | Uncertain significance (Jan 12, 2018) | ||
19-12891219-A-G | Glutaric aciduria, type 1 | Benign (Jun 10, 2021) | ||
19-12891219-AGC-GG | not specified | Likely benign (Mar 10, 2017) | ||
19-12891221-C-T | Likely benign (Mar 14, 2018) | |||
19-12891260-C-A | Glutaric aciduria, type 1 | Uncertain significance (Dec 18, 2024) | ||
19-12891301-G-C | Glutaric aciduria, type 1 • GCDH-related disorder | Uncertain significance (May 10, 2021) | ||
19-12891305-A-C | Glutaric aciduria, type 1 | Likely pathogenic (Dec 20, 2022) | ||
19-12891305-A-G | Pathogenic (Mar 02, 2023) | |||
19-12891307-G-A | Glutaric aciduria, type 1 | Likely pathogenic (Mar 28, 2017) | ||
19-12891310-C-T | Glutaric aciduria, type 1 | Likely benign (Sep 10, 2023) | ||
19-12891310-CCT-C | Glutaric aciduria, type 1 | Likely pathogenic (Mar 11, 2023) | ||
19-12891311-C-T | Glutaric aciduria, type 1 | Likely benign (Oct 05, 2022) | ||
19-12891311-C-CT | Glutaric aciduria, type 1 | Pathogenic (Apr 12, 2020) | ||
19-12891319-C-A | Glutaric aciduria, type 1 • not specified | Likely benign (Apr 28, 2023) | ||
19-12891319-C-T | Glutaric aciduria, type 1 | Likely benign (Dec 11, 2023) | ||
19-12891333-T-C | Glutaric aciduria, type 1 | Uncertain significance (Aug 14, 2020) | ||
19-12891342-G-A | Glutaric aciduria, type 1 • GCDH-related disorder | Conflicting classifications of pathogenicity (Jan 04, 2024) | ||
19-12891345-GA-T | Glutaric aciduria, type 1 | Likely pathogenic (Jun 28, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
GCDH | protein_coding | protein_coding | ENST00000222214 | 11 | 23182 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00486 | 0.994 | 125689 | 0 | 59 | 125748 | 0.000235 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.306 | 247 | 261 | 0.947 | 0.0000175 | 2821 |
Missense in Polyphen | 96 | 117.27 | 0.8186 | 1293 | ||
Synonymous | -0.144 | 118 | 116 | 1.02 | 0.00000873 | 915 |
Loss of Function | 2.85 | 8 | 22.6 | 0.354 | 0.00000118 | 249 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000556 | 0.000556 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.00125 | 0.00125 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000971 | 0.0000967 |
Middle Eastern | 0.00125 | 0.00125 |
South Asian | 0.000131 | 0.000131 |
Other | 0.000333 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA and CO(2) in the degradative pathway of L-lysine, L-hydroxylysine, and L-tryptophan metabolism. It uses electron transfer flavoprotein as its electron acceptor. Isoform Short is inactive. {ECO:0000269|PubMed:17176108, ECO:0000269|PubMed:6423663, ECO:0000269|PubMed:8541831}.;
- Pathway
- Tryptophan metabolism - Homo sapiens (human);Lysine degradation - Homo sapiens (human);Fatty acid degradation - Homo sapiens (human);Long chain acyl-CoA dehydrogenase deficiency (LCAD);Lysine Degradation;Hyperlysinemia I, Familial;2-aminoadipic 2-oxoadipic aciduria;Trifunctional protein deficiency;Carnitine palmitoyl transferase deficiency (II);Very-long-chain acyl coa dehydrogenase deficiency (VLCAD);Medium chain acyl-coa dehydrogenase deficiency (MCAD);Pyridoxine dependency with seizures;Saccharopinuria/Hyperlysinemia II;Short Chain Acyl CoA Dehydrogenase Deficiency (SCAD Deficiency);Fatty acid Metabolism;Glutaric Aciduria Type I;Glutaric Aciduria Type I;Ethylmalonic Encephalopathy;Hyperlysinemia II or Saccharopinuria;Carnitine palmitoyl transferase deficiency (I);Fatty Acid Beta Oxidation;Tryptophan metabolism;Lysine catabolism;Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism;Metabolism of amino acids and derivatives;Saturated fatty acids beta-oxidation;Metabolism;Lysine degradation;Lysine metabolism;glutaryl-CoA degradation;Tryptophan degradation
(Consensus)
Recessive Scores
- pRec
- 0.684
Intolerance Scores
- loftool
- 0.0905
- rvis_EVS
- -0.51
- rvis_percentile_EVS
- 21.65
Haploinsufficiency Scores
- pHI
- 0.0809
- hipred
- Y
- hipred_score
- 0.528
- ghis
- 0.501
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.998
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Gcdh
- Phenotype
- homeostasis/metabolism phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); renal/urinary system phenotype;
Gene ontology
- Biological process
- lysine catabolic process;tryptophan metabolic process;fatty acid beta-oxidation using acyl-CoA dehydrogenase;fatty-acyl-CoA biosynthetic process
- Cellular component
- mitochondrion;mitochondrial matrix
- Molecular function
- fatty-acyl-CoA binding;glutaryl-CoA dehydrogenase activity;flavin adenine dinucleotide binding